论文部分内容阅读
目的:评价降纤酶与低分子肝素联合治疗急性脑梗死的临床疗效及安全性。方法:对157例急性脑梗死病例随机分为降纤酶组、低分子肝素组、降纤酶与低分子肝素联合组及对照组,4组均采用血栓通和胞二磷胆碱作为基础治疗。降纤酶10 U静脉滴注1次/日,连用3 d,低分子肝素腹壁皮下注射2次/日,连用10 d。分别于治疗前及治疗后1周、2周时评定神经功能缺损评分。结果:降纤酶组与低分子肝素组临床疗效优于对照组。而联合治疗组疗效又优于前两组,且无颅内出血等严重并发症。结论:降纤酶与低分子肝素联合治疗急性脑梗死临床疗效优于单独使用,且安全。
Objective: To evaluate the clinical efficacy and safety of defibrase combined with low molecular weight heparin in the treatment of acute cerebral infarction. Methods: 157 cases of acute cerebral infarction were randomly divided into defibrase group, low molecular weight heparin group, defibrase and low molecular weight heparin combined group and control group, 4 groups were treated with thrombosis and citicoline as the basic treatment . Defibrase 10 U intravenously 1 / day, once every 3 d, low molecular weight heparin subcutaneous injection 2 times / day, once every 10 d. Neurological deficit scores were assessed before treatment and 1 week and 2 weeks after treatment, respectively. Results: The clinical efficacy of defibrase and low molecular weight heparin group was better than that of the control group. The combination therapy group is superior to the first two groups, and no serious complications such as intracranial hemorrhage. Conclusion: The clinical efficacy of defibrase combined with low molecular weight heparin in the treatment of acute cerebral infarction is superior to that used alone and safe.